Anthony Wierzbicki DPhil, DM, FRCPath, FAHA, Timothy Hardman PhD, Adie Viljoen FRCPath
{"title":"Drugs in development for the management of dyslipidaemia","authors":"Anthony Wierzbicki DPhil, DM, FRCPath, FAHA, Timothy Hardman PhD, Adie Viljoen FRCPath","doi":"10.1002/fps.93","DOIUrl":null,"url":null,"abstract":"<p>Lipid-lowering is established as proven intervention to reduce atherosclerosis. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipo protein cholesterol (LDL-C), <i>eg</i> antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, <i>eg</i> novel peroxisomal proliferator activating receptors (PPAR) agonists, MTPIs; HDL: delipidation strategies and cholesterol ester transfer protein inhibitors (CETPIs) and modulators of inflammation, <i>eg</i> phospholipase inhibitors. Copyright © 2012 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"12-15"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.93","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lipid-lowering is established as proven intervention to reduce atherosclerosis. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipo protein cholesterol (LDL-C), eg antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, eg novel peroxisomal proliferator activating receptors (PPAR) agonists, MTPIs; HDL: delipidation strategies and cholesterol ester transfer protein inhibitors (CETPIs) and modulators of inflammation, eg phospholipase inhibitors. Copyright © 2012 John Wiley & Sons, Ltd.
治疗血脂异常的药物正在开发中
降脂已被证实是减少动脉粥样硬化的干预措施。他汀类药物是治疗的基础，但不能治疗血脂异常的所有方面。许多新的治疗化合物正在开发中。这些包括低密度脂蛋白胆固醇(LDL-C)的额外治疗，例如反义寡核苷酸或微粒体转移蛋白抑制剂(MTPI);甘油三酯，如新型过氧化物酶体增殖物激活受体(PPAR)激动剂(mtpi);HDL:脱脂策略、胆固醇酯转移蛋白抑制剂(cetpi)和炎症调节剂，如磷脂酶抑制剂。版权所有©2012 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
